Cargando…
Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer
IMPORTANCE: Evidence regarding real-world effectiveness of therapies for patients with advanced non–small cell lung cancer (NSCLC) whose tumors are resistant to platinum-based chemotherapy is lacking. OBJECTIVE: To compare the effectiveness of the immune checkpoint inhibitors atezolizumab (programme...
Autores principales: | Ramagopalan, Sreeram, Gupta, Alind, Arora, Paul, Thorlund, Kristian, Ray, Joshua, Subbiah, Vivek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590169/ https://www.ncbi.nlm.nih.gov/pubmed/34767024 http://dx.doi.org/10.1001/jamanetworkopen.2021.34299 |
Ejemplares similares
-
Assessment of Alectinib vs Ceritinib in ALK-Positive Non–Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data
por: Wilkinson, Samantha, et al.
Publicado: (2021) -
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non–Small Cell Lung Cancer
por: Popat, Sanjay, et al.
Publicado: (2022) -
Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non–Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment
por: Ramagopalan, Sreeram V., et al.
Publicado: (2022) -
Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
por: Alonso-García, Miriam, et al.
Publicado: (2022) -
The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy
por: Ramagopalan, Sreeram, et al.
Publicado: (2021)